Subtopic Deep Dive
HER2-Positive Gastric Cancer Therapy
Research Guide
What is HER2-Positive Gastric Cancer Therapy?
HER2-Positive Gastric Cancer Therapy uses trastuzumab-based regimens combined with chemotherapy for advanced cases with HER2 overexpression.
The ToGA trial by Bang et al. (2010) established trastuzumab plus chemotherapy as standard, improving survival in 22% of HER2-positive patients (7120 citations). Trastuzumab deruxtecan showed superior response rates in pretreated patients per Shitara et al. (2020, 1199 citations). Guidelines like NCCN by Ajani et al. (2022) recommend HER2 testing for targeted therapy eligibility (1575 citations).
Why It Matters
HER2-targeted therapy benefits 15-20% of gastric cancer patients with overexpression, extending median survival from 11.1 to 13.8 months as shown in ToGA (Bang et al., 2010). Trastuzumab deruxtecan offers second-line options with 51% response rate versus 14% for chemotherapy (Shitara et al., 2020). ESMO guidelines by Okines et al. (2010) integrate these into practice, influencing global standards. NCCN updates by Ajani et al. (2022) guide biomarker-driven treatment in advanced disease.
Key Research Challenges
HER2 Testing Heterogeneity
IHC and FISH discordance affects 10-20% of cases, complicating eligibility (Smyth et al., 2020). Standardized scoring like ToGA criteria improves consistency but varies by lab (Bang et al., 2010). Japanese guidelines note regional biomarker differences (2018 edition).
Primary and Acquired Resistance
Up to 60% of ToGA patients show intrinsic resistance despite HER2 positivity (Bang et al., 2010). Mechanisms include PI3K/AKT pathway activation, limiting trastuzumab efficacy (Joshi and Badgwell, 2021). Novel agents like deruxtecan address some but myelosuppression arises (Shitara et al., 2020).
Optimal Combination Regimens
Trastuzumab with cisplatin/fluoropyrimidine sets benchmark, but doublet versus triplet chemotherapy outcomes vary (Bang et al., 2010). NCCN guidelines recommend capecitabine/oxaliplatin plus trastuzumab for advanced disease (Ajani et al., 2022). Post-ToGA trials explore immunotherapy additions amid resistance (Smyth et al., 2020).
Essential Papers
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung‐Jue Bang, Eric Van Cutsem, A. Feyereislova et al. · 2010 · The Lancet · 7.1K citations
Gastric cancer
Elizabeth Smyth, Magnus Nilsson, Heike I. Grabsch et al. · 2020 · The Lancet · 4.5K citations
Japanese gastric cancer treatment guidelines 2014 (ver. 4)
Surgery for gastric cancer is defined as follows in the order of the stomach volume to be resected. · 2016 · Gastric Cancer · 2.5K citations
Japanese gastric cancer treatment guidelines 2018 (5th edition)
The algorithm is shown in Fig., . Description of the tumor status (T/N/M and stage) in this edition is based on the 15th edition of the Japanese Classification of Gastric Carcinoma [, which is identical to the 8th edition of the International Union Against Cancer (UICC)/TNM Classification [ · 2020 · Gastric Cancer · 1.7K citations
Current treatment and recent progress in gastric cancer
Smita S. Joshi, Brian D. Badgwell · 2021 · CA A Cancer Journal for Clinicians · 1.7K citations
Abstract Gastric cancer is not a top‐10 malignancy in the United States but represents one of the most common causes of cancer death worldwide. Biological differences between tumors from Eastern an...
Comprehensive review of targeted therapy for colorectal cancer
Yuanhong Xie, Yingxuan Chen, Jing‐Yuan Fang · 2020 · Signal Transduction and Targeted Therapy · 1.6K citations
Abstract Colorectal cancer (CRC) is among the most lethal and prevalent malignancies in the world and was responsible for nearly 881,000 cancer-related deaths in 2018. Surgery and chemotherapy have...
Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Jaffer A. Ajani, Thomas A. D’Amico, David J. Bentrem et al. · 2022 · Journal of the National Comprehensive Cancer Network · 1.6K citations
Gastric cancer is the third leading cause of cancer-related deaths worldwide. Over 95% of gastric cancers are adenocarcinomas, which are typically classified based on anatomic location and histolog...
Reading Guide
Foundational Papers
Start with ToGA trial (Bang et al., 2010) for phase 3 evidence of trastuzumab efficacy. Follow with ESMO guidelines (Okines et al., 2010) for diagnostic integration.
Recent Advances
Study DESTINY-Gastric01 (Shitara et al., 2020) for deruxtecan outcomes. Review NCCN 2022 (Ajani et al.) and Lancet overview (Smyth et al., 2020) for current standards.
Core Methods
HER2 assessment via IHC/FISH. Regimens: trastuzumab + chemo (ToGA). Antibody-drug conjugates (deruxtecan). Survival analysis by Kaplan-Meier, HR from Cox models.
How PapersFlow Helps You Research HER2-Positive Gastric Cancer Therapy
Discover & Search
Research Agent uses searchPapers('HER2-positive gastric cancer trastuzumab deruxtecan') to retrieve Shitara et al. (2020), then citationGraph reveals ToGA (Bang et al., 2010) as top cited predecessor, and findSimilarPapers uncovers NCCN guidelines (Ajani et al., 2022). exaSearch handles nuanced queries like 'HER2 resistance mechanisms gastric cancer post-ToGA'.
Analyze & Verify
Analysis Agent applies readPaperContent on ToGA trial to extract HR 0.74 survival data, verifyResponse with CoVe cross-checks against Shitara et al. (2020) for consistency, and runPythonAnalysis plots Kaplan-Meier curves from extracted OS/PFS stats using matplotlib. GRADE grading scores ToGA as high-quality evidence for phase 3 RCT design.
Synthesize & Write
Synthesis Agent detects gaps like post-deruxtecan third-line options via contradiction flagging across Joshi and Badgwell (2021) and Smyth et al. (2020). Writing Agent uses latexEditText for therapy algorithm revisions, latexSyncCitations integrates 20+ refs, latexCompile generates PDF, and exportMermaid diagrams resistance pathways.
Use Cases
"Extract and plot survival curves from ToGA and DESTINY-Gastric01 trials"
Research Agent → searchPapers → Analysis Agent → readPaperContent + runPythonAnalysis (pandas survival analysis, matplotlib KM plots) → researcher gets overlaid HR/confidence intervals CSV.
"Draft LaTeX review section on HER2 therapy guidelines evolution"
Synthesis Agent → gap detection → Writing Agent → latexEditText (insert ToGA/NCCN summaries) → latexSyncCitations (Bang 2010, Ajani 2022) → latexCompile → researcher gets compiled PDF with figure.
"Find code for HER2 gastric cancer biomarker analysis"
Research Agent → paperExtractUrls (from Joshi 2021) → paperFindGithubRepo → githubRepoInspect (R scripts for IHC scoring) → researcher gets validated biomarker simulation notebook.
Automated Workflows
Deep Research workflow scans 50+ papers via searchPapers on 'HER2 gastric therapy outcomes', structures report with GRADE-scored evidence from ToGA and DESTINY. DeepScan's 7-step chain verifies resistance claims: readPaperContent → CoVe → runPythonAnalysis on meta-HR. Theorizer generates hypotheses on dual HER2/Claudin18.2 targeting from guideline contradictions (Ajani 2022, Japanese 2018).
Frequently Asked Questions
What defines HER2-positive gastric cancer?
HER2 positivity requires IHC 3+ or IHC 2+ with FISH amplification, per ToGA criteria (Bang et al., 2010). Occurs in 15-20% of advanced cases (Smyth et al., 2020).
What are standard methods in HER2 therapy?
First-line: trastuzumab + cisplatin/fluoropyrimidine or capecitabine/oxaliplatin (Bang et al., 2010; Ajani et al., 2022). Second-line: trastuzumab deruxtecan (Shitara et al., 2020). NCCN and ESMO endorse HER2 testing pre-treatment (Okines et al., 2010).
What are key papers?
ToGA trial (Bang et al., 2010, 7120 citations) established standard. DESTINY-Gastric01 (Shitara et al., 2020, 1199 citations) advanced antibody-drug conjugates. NCCN guidelines (Ajani et al., 2022, 1575 citations) summarize regimens.
What open problems remain?
Overcoming resistance in 60-80% non-responders (Bang et al., 2010). Biomarker refinement beyond HER2 (Joshi and Badgwell, 2021). Third-line options post-deruxtecan (Smyth et al., 2020).
Research Gastric Cancer Management and Outcomes with AI
PapersFlow provides specialized AI tools for your field researchers. Here are the most relevant for this topic:
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Deep Research Reports
Multi-source evidence synthesis with counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
AI Academic Writing
Write research papers with AI assistance and LaTeX support
Start Researching HER2-Positive Gastric Cancer Therapy with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.